

Gilde Healthcare's Impact Council

Chaired by Professor Guido Rasi, former Executive Director of the European Medicines Agency (EMA), Gilde's Impact Council plays a pivotal role in supporting Gilde and its portfolio companies in their collective mission to provide better care at lower cost.

Professor Guido Rasi, Chair

- Former Executive Director of the European Medicines Agency
- Worked as a physician and professor in microbiology



Dr. Kim Caldwell

- Former senior executive at Humana and CMS
- 4 decades of experience in US payer, PBM, Pharmaceuticals



Professor Carole Longson

- Former Executive Director of NICE (UK)
- Former CSO of British Pharma industry association



David Haerry

- Former co-Chair of EMA's patient and consumer working party
- Executive at EUPATHI and Patvocates



Dr. Christina Akerman

- President of ICHOM (patient-reported outcomes)
- Former Director General of the MPA in Sweden



Dr. Dan Ollendorf

- Current Director of Value Measurement at Tufts
- Former CSO of ICER (US)



Dr. Brian O'Rourke

- Former President and CEO of CADTH (Canadian HTA)
- Incoming Chair at IPSOR (leading professional society for health economics and outcomes research)



Dr. Michael Jaff

- Paul and Phyllis Fireman Endowed Chair in Vascular Medicine at the Massachusetts General Hospital
- Former President of Newton-Wellesley hospital (part of Mass General Brigham Health System)



Gilde's Impact Council consists of 8 leading international experts who collectively represent key stakeholders in the healthcare sector, including patients, healthcare professionals, regulatory bodies, industry, health technology assessment bodies and the payer community.

Since the launch of the Impact Council at the end of 2022, Gilde has organized multiple interactions between its portfolio companies and members of the council. This has led to seven concrete projects so far, where committee members have advised portfolio companies on key regulatory questions, engagement strategies with the payer and HTA communities, how to build effective relationships within the patient community, etc. These interactions are very well-received by Gilde's portfolio companies as they do not only provide key learning opportunities, but also help significantly in terms of further streamlining and focusing development and commercialization processes.